Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain – Anti-abuse opioids set to prosper

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain – Anti-slander opioids set to prosper

The subdue to severe chronic nociceptive pain emporium has boomed in the years seeing that the removal of generic extended-exoneration oxycodone from the US, growing in regard to eclipse $10 billion. However, this respite will be short-lived with the pipeline and recently-launched drugs unable to fill the unreal left by generic erosion of OxyContin (controlled-deliver oxycodone, Purdue).

Buy Now: Commercial Insight Market

Browse whole Research Reports On : Opiodis Market

Scope

Analysis of unrepining segmentation, epidemiology, current treatment approaches, the persevering acquisition process and clinical unmet indispensably

Breakdown of historic (200509) and coming time (201019) prescription sales across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK)

Review of clew pipeline trends, issues in clinical hardship design and the implications of Risk Evaluation and Mitigation Strategies required ~ means of the FDA

Commercial and clinical impost of key late-stage pipeline drugs, through key opinion leader comment and space-specific sales forecasts to 2019

Highlights

Aided by continued growth of OxyContin and the cast of opioids incorporating anti-abuse technologies, the mart is set to peak at $11.7 billion in 2012. Thereafter, the mart will contract to reach $10.5 billion in 2019, when the effect of patent expiries in successi~ key brands offsets sales growth of newly come drugs.

Nucynta ER is the principally clinically and commercially attractive pipeline medicine, eclipsing the gold standard OxyContin. Backed ~ dint of. Johnson & Johnson, Nucynta ER is provide against to make a significant impact with the market. Remoxy (extended-release oxycodone, King) and EG-P066 (extended-dispensation morphine) are also both expected to cast of the face as leading brands.

Expectations of the modern anti-NGF class have been dampened following revelations of the osteoarthritis-worsening take ~s effects of tanezumab (RN624, Pfizer). Datamonitor predicts that tanezumab, every NGF monoclonal antibody, will reach the market; however, as a last line therapy in sharp cancer pain.

Reasons to Purchase

Quantify the current and subsequent time size of the moderate to cruel chronic nociceptive pain market

Understand the country-specific impact of key events in the quell to severe chronic nociceptive pain place of traffic during the forecast period 2010-19

Identify in posse licensing opportunities based on product portfolios and anticipated mart needs